Top CD Rates on May 23 2026 Leading Account Offers 4 APY Amid Changing Rate Landscape Neelkanth Mishra Projects Repo Rate Could Approach Decade Low Markets May See Recovery from December CBS and Paramount Withdraw Copyright Claims After Stephen Colberts Viral Parody UK Government Proposes VAT Reduction for Theme Parks and Childrens Meals to Ease CostofLiving Burden Trump Delays AI Executive Order Signing Cites Concerns Over Potential Regulatory Overreach Novartis Lifts FullYear Guidance on Strong Operational Momentum OC Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response Kiniksa Pharmaceuticals KNSA Q1 2026 Earnings EPS Surprises to the Upside as Stock Dips ASTH Q1 2026 Earnings EPS Misses Estimates Slight Stock Decline APH Q1 2026 Earnings Stellar EPS Surprise Drives Strong Stock Rally HGTY Q1 2026 Earnings NarrowerThanExpected Loss Drives Small Beat Shares Slip ICON Q4 2025 Earnings EPS Misses Estimates Amidst Operational Challenges ATT T Holds Steady Near Support as Telecom Sector Faces Mixed Signals SPACSphere Rights SSACR Hold Steady at 016 as Trading Volume Remains Subdued Ardagh Metal Packaging AMBP Nears Key Support Level After Minor Decline Coinbase Global COIN Slips Over 4 as Crypto Headwinds Intensify Corbus Pharmaceuticals CRBP Under Pressure at 782 Key Support and Resistance in Focus Heartbeam Inc BEAT Q1 2026 Earnings EPS Beat Drives Positive Surprise but Revenue Concerns May Weigh on Sentiment Ernexa Therapeutics ERNA Q3 2023 Earnings ClinicalStage Biotech Reports Net Loss as Stock Declines LMFA Q1 2026 Earnings EPS Misses Estimates as Company Reports Wider Loss INMD Q1 2026 Earnings Earnings Miss as EPS Falls Short of Estimates Lucid Group LCID Q1 2026 Earnings Wider Loss Than Expected as Production Ramp Challenges Persist NXST Q1 2026 Earnings EPS Surges Past Estimates on Strong Operational Performance Stellantis Turnaround Plan Prediction Market Regulation Oura IPO Filing Lead CNBC Morning Squawk GFS Q1 2026 Earnings EPS Surprises to the Upside Amid Strategic Cost Discipline Vistagen Therapeutics VTGN Approaches Key Support After Marginal Decline